Last mentioned: Feb 26, 2026
Agilent reported a resilient first quarter despite weather disruptions and tariff-driven margin pressure, while TJX capped a record fiscal year with $60.4 billion in sales. Both companies highlighted shifting consumer and industrial demand, with Agilent navigating soft academic markets and TJX leveraging inventory flexibility to drive 5% comparable sales growth.
Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
TJX Companies achieved a milestone $60.4 billion in annual sales, driven by a 5% comparable sales increase and improved shrink management. Conversely, Agilent Technologies reported a 100-basis point gross margin decline due to tariff headwinds and softening demand in government-funded sectors.
Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.